Regulation of PAI-1 concentration in platelets by systemic administration of antisense oligonucleotides to rats

Thrombosis and Haemostasis

Volumn 85, Issue 6, 2001, Pages 1086-1089

  Pawlowska, Z ^a   Chabielska, E ^a   Kobylanska, A ^a   Maciaszek, A ^a   Swiatkowska, M ^a   Buczko, W ^a   Stec, W J ^a   Cierniewski, C S ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antisense oligonucleotides; Blood platelets; PAI 1

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; MPO 16R; PLASMINOGEN ACTIVATOR INHIBITOR 1; PO 16R; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; MALE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0034971351     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615968     Document Type: Article

References (32)

1. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets
2. Studies on the release of a plasminogen activator inhibitor by human platelets
3. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction
4. Platelet factor Va is responsible for the majority of the antifibrinolytic effect of platelets
5. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood
6. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation
7. Immunological relationship between plasminogen activator inhibitors from different sources
8. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and PAI-1 content and distribution
9. Platelets and endothelial cells act in concert to delay thrombolysis - Evidence from an in vitro model of the human occlusive thrombus
10. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis
11. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia
12. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
13. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
14. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
15. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
16. Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: Evidence for a key role of endothelial cells in thrombolytic resistance
17. Phosphorothioate oligodeoxyribonucleotides antisense to PAI-1 mRNA increase fibrinolysis and modify experimental thrombosis in rats
18. Plasminogen: Purification from human plasma by affinity chromatography
19. Inhibition of PAI-1 release in EA.hy 926 cell cultures by 5′-end lipophilic modification of oligodeoxyribonucleotides
20. Induction of experimental arterial occlusive thrombi in rats
21. A miniaturized fibrinolytic assay for plasminogen activators
22. Bleeding time in rats: A comparison of different experimental conditions
23. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats
24. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy
25. The cytotoxicity of anti-PAI-1 oligonucleotides and their conjugates
26. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets
27. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states
28. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease
29. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases
30. The relationship between impaired fibrinolysis and coronary heart disease: A role for PAI-1
31. Plasminogen activator inhibitor-1 and atherothrombosis
32. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity